Alzheimer’s disease is the most common cause of major neurocognitive disorder and and while largely managed with non-pharmacologic interventions, there are also a variety of pharmacotherapeutics available for use when appropriate. Which of the following is considered a first-line pharmacologic intervention for symptom control in the patient with Alzheimer’s disease?
A. Lecanemab
B. Donepezil
C. Memantine
D. Namzaric®
---
YouTube: https://www.youtube.com/watch?v=-z2D99MLGuM&list=PLf0PFEPBXfq5HGfNV-GbOlYHtDwd35OeG&index=34
